Liquid formulation
AssigneeLuoda Pharma Pty Ltd
InventorsNicholas Bova, Stephen Page, Giuseppe Pippia
Life of this patent
Estimating the term…
Abstract
The invention relates to a liquid formulation comprising propylene glycol and an effective amount of an inodilator, an angiotensin converting enzyme inhibitor, or a combination of an inodilator and an angiotensin converting enzyme inhibitor and to use of the formulation for treating cardiac disease and/or hypertension.
Claims7
An orally bioavailable liquid formulation comprising 7 wt % to about 65 wt % of the total formulation of propylene glycol and a combination of an inodilator selected from the group consisting of pimobendan, a pharmaceutically acceptable salt thereof, and a veterinary acceptable salt thereof, and an angiotensin converting enzyme inhibitor selected from the group consisting of enalapril, benazepril, a pharmaceutically acceptable salt thereof, and a veterinary acceptable salt thereof;
- wherein the inodilator and/or the angiotensin converting enzyme inhibitor is present in an amount of about 0.1 wt % to about 50 wt % of the total formulation.
A liquid formulation comprising 7 wt % to about 65 wt % of the total formulation of propylene glycol and an effective amount of a combination of an inodilator selected from the group consisting of pimobendan, a pharmaceutically acceptable salt thereof, and a veterinary acceptable salt thereof and an angiotensin converting enzyme inhibitor selected from the group consisting of enalapril, benazepril, a pharmaceutically acceptable salt thereof, and a veterinary acceptable salt thereof.
Dependencies are inferred from the claim text.